The possibilities of using piribedil in terms of evidence-based medicine
A.A. Pilipovich, V. L. Golubev

Sechenov University, Moscow

The article reviews the data of modern foreign and domestic literature on the use of piribedil as one of the dopamine agonists for the main indications: Parkinson’s disease, moderate cognitive impairment and sensory deficiency in elderly patients. Such a multiple use of this drug is due to its unique mechanisms of action that distinguish it from other dopamine agonists. The mechanisms of action of the drug are discussed. The data of the main clinical studies of the efficacy and safety of piribedil are given. The Movement Disorder Society (MDS-EBM) estimates that pyribedil is «effective» and «clinically useful» for the symptomatic treatment of patients at the early stages of Parkinson’s disease both as monotherapy and in combination with levodopa. The drug reduces the main motor symptoms of parkinsonism, and also has a positive effect on non-motor disorders: depression, apathy, cognitive decline. The positive effect of piribedil on cognitive function has been shown in more than 10 foreign clinical trials involving about 7000 patients and in a significant number of domestic works. This effect is successfully used in various types of cognitive disorders, both neurodegenerative and vascular, of mild to moderate severity.

Key words: moderate cognitive impairment, Parkinson’s disease, dopamine agonists, piribedil, Pronoran.
For citation: Pilipovich A.A., Golubev V. L. The possibilities of using piribedil in terms of evidence-based medicine // RMJ. 2018. № 12(I). P. 39–43.